Market Research Logo

Global Graft vs Host Disease (GVHD) Treatment Market 2017-2021

Global Graft vs Host Disease (GVHD) Treatment Market 2017-2021

About Graft vs Host Disease (GVHD) Treatment

Graft-versus-host disease (GVHD) is an immune-mediated disease, which results from a multifaceted interaction amongst donor and recipient's adaptive immunity. GVHD is an induced indication and emerges post organ or tissue transplant. The probability of developing GVHD is higher in allogeneic transplant, a transplant where donor's organ/cell are used for transplantation compared with autologous transplant, a transplant where individual's cells have been used for transplant.

Technavio’s analysts forecast the global graft vs host disease (GVHD) treatment market to grow at a CAGR of 7.15% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global graft vs host disease (GVHD) treatment market for 2017-2021. To calculate the market size, the report considers sales of branded, generic, and off-label drugs.The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Graft vs Host Disease (GVHD) Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Bristol-Myers Squibb
  • Novartis
  • Pfizer
  • F. Hoffmann-La Roche
Other prominent vendors
  • Abbott
  • AbbVie
  • Allergan
  • Anterogen
  • Astellas Pharma
  • Athersys
  • Baxter
  • Caladrius
  • Cellular Biomedicine Group
  • Cipla
  • Eisai
  • Eli Lilly
  • GlaxoSmithKline
  • Glenmark
  • Helsinn Healthcare
  • Heron Therapeutics
  • Incyte Corporation
  • IPCA Laboratories
  • Kadmon Holdings
  • Lupin
  • Osiris Therapeutics
  • RedHill
  • Sanofi
  • Shire
  • Sun Pharmaceutical Industries
  • Takeda Pharmaceutical
  • ViaCyte
Market driver
  • Increased prevalence of cancer
  • For a full, detailed list, view our report
Market challenge
  • Off-label use of drugs
  • For a full, detailed list, view our report
Market trend
  • Inorganic growth strategies
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Graft vs Host Disease (GVHD) Treatment Market 2017-2021

Technavio recognizes the following companies as the key players in the global graft vs host disease (GVHD) treatment market: Bristol-Myers Squibb, Novartis, Pfizer, and F. Hoffmann-La Roche.

Other Prominent Vendors in the market are: bbott, AbbVie, Allergan, Anterogen, Astellas Pharma, Athersys, Baxter, Caladrius, Cellular Biomedicine Group, Cipla, Eisai, Eli Lilly, GlaxoSmithKline, Glenmark, Helsinn Healthcare, Heron Therapeutics, Incyte Corporation, IPCA Laboratories, Kadmon Holdings, Lupin, Osiris Therapeutics, RedHill, Sanofi, Shire, Sun Pharmaceutical Industries, Takeda Pharmaceutical, and ViaCyte.

Commenting on the report, an analyst from Technavio’s team said: “One trend in the market is inorganic growth strategies. The inorganic growth strategies are expected to contribute the growth of GVHD treatment market as the market is completely based on off-label usage. These inorganic growth strategies include global merger and acquisition, partnerships and regional acquisition.”

According to the report, one driver in the market is increased prevalence of cancer. Globally, cancer is one of the life-threating diseases. As per National Institutes of Health (NIH), it is the second largest cause of death globally. As per National Cancer Institute, in the US alone, 1,685,210 new cancer cases and 595,690 cancer deaths were expected during 2016. The prevalence of this disease is growing at high rates and is expected to grow at higher rates in future too. Bone marrow transplant is widely preferred in various types of cancers.

Further, the report states that one challenge in the market is off-label use of drugs. GVHD is one of the clinical disorders arising due to tissue and organ transplantation. It is more commonly observed in allogeneic transplants where the tissue or organ from another donor is transplanted into an individual. There is no specific drug indicated for GVHD, and thus the current management of GVHD is based on the off-label use of various drug therapies. This off-label use of drugs is one of the biggest challenges in the global GVHD treatment market till date.

Companies Mentioned

Bristol-Myers Squibb, Novartis, Pfizer, F. Hoffmann-La Roche, bbott, AbbVie, Allergan, Anterogen, Astellas Pharma, Athersys, Baxter, Caladrius, Cellular Biomedicine Group, Cipla, Eisai, Eli Lilly, GlaxoSmithKline, Glenmark, Helsinn Healthcare, Heron Therapeutics, Incyte Corporation, IPCA Laboratories, Kadmon Holdings, Lupin, Osiris Therapeutics, RedHill, Sanofi, Shire, Sun Pharmaceutical Industries, Takeda Pharmaceutical, and ViaCyte.

  • Executive summary
  • Scope of the report
  • Research Methodology
  • Introduction
    • Table Mechanism of GVHD
    • Table Global GVHD treatment market growth promoters
  • Disease overview
    • Table Major acute GVHD symptoms
    • Table Major chronic GVHD symptoms
  • Market overview
    • Table Global GVHD treatment market 2016-2021 ($ millions)
    • Table Opportunity analysis in global GVHD treatment market
    • Five forces analysis
      • Table Five forces analysis
  • Pipeline landscape
    • Table Pipeline molecules as per vendors
    • Table Key clinical trials
  • Market segmentation by disease type
    • Table Segmentation of global GVHD treatment market by disease type 2016
    • Acute GVHD
      • Table Symptoms in acute GVHD
      • Table Global acute GVHD treatment market 2016-2021 ($ millions)
      • Table Symptoms in chronic GVHD
      • Table Global chronic GVHD treatment market 2016-2021 ($ millions)
  • Geographical segmentation
    • Table Segmentation of global GVHD treatment market by geography 2016 and 2021
    • Table Segmentation of global GVHD treatment market revenue by geography 2016-2021 ($ millions)
    • GVHD treatment market in Americas
      • Table Market scenario in Americas
      • Table GVHD treatment market in Americas 2016-2021 ($ millions)
    • GVHD treatment market in EMEA
      • Table Market scenario in EMEA
      • Table GVHD treatment market in EMEA 2016-2021 ($ millions)
    • GVHD treatment market in APAC
      • Table Market scenario in APAC
      • Table GVHD treatment market in APAC 2016-2021 ($ millions)
  • Decision framework
  • Drivers and challenges
    • Market drivers
      • Table Percentage distribution of transplants by organ in US (1988-2016)
      • Table Various major types of cancers managed by bone marrow transplant
    • Market challenges
      • Table Various off-label drugs used in the management of GVHD
      • Table Various symptoms and disorders associated with GVHD
      • Table Legal and ethical issues in countries
  • Market trends
    • Inorganic growth strategies
      • Table Inorganic growth strategies
    • Newer applications of bone marrow transplant
      • Table Newer applications of bone marrow transplant
    • Growing focus toward the use of biologics
  • Vendor landscape
    • Competitive scenario
      • Table Competitive structure analysis of global GVHD treatment market 2016
      • Table Market penetration of various GVHD drugs manufacturers worldwide 2016
      • Table Strategic success factors of companies in global GVHD treatment market
  • Key vendor analysis
    • Bristol-Myers Squibb
      • Table Bristol-Myers Squibb: Key highlights
      • Table Bristol-Myers Squibb: Strength assessment
      • Table Bristol-Myers Squibb: Strategy assessment
      • Table Bristol-Myers Squibb: Opportunity assessment
    • F. Hoffmann-La Roche
      • Table F. Hoffmann-La Roche: Key highlights
      • Table F. Hoffmann-La Roche: Strength assessment
      • Table F. Hoffmann-La Roche: Strategy assessment
      • Table F. Hoffmann-La Roche: Opportunity assessment
    • Novartis
      • Table Novartis: Key highlights
      • Table Novartis: Strength assessment
      • Table Novartis: Strategy assessment
      • Table Novartis: Opportunity assessment
    • Pfizer
      • Table Pfizer: Key highlights
      • Table Pfizer: Strength assessment
      • Table Pfizer: Strategy assessment
      • Table Pfizer: Opportunity assessment
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report